Group 1 - The core point of the article is that Xiansheng Pharmaceutical (02096.HK) announced that its drug Enzeshou® (Suvorexant injection) has been officially included in the National Medical Insurance Drug List (2025) by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, effective from January 1, 2026 [1] - Additionally, the drug Endu® (Recombinant Human Endothelial Inhibitor Injection) has successfully completed the renewal process for the National Medical Insurance Drug List (NRDL) [1]

Core Viewpoint - The announcement by the company indicates that its drug Enze Shu® (suvorexant injection) has been officially included in the National Medical Insurance Catalog for 2025, effective from January 1, 2026, which is a significant milestone for the company and its product portfolio [1][4]. Group 1: Drug Approvals and Listings - Enze Shu® has been approved for the treatment of adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have received no more than one prior systemic therapy and are platinum-resistant [1][4]. - The drug was granted market approval in China on June 30, 2025, marking its entry into the competitive oncology market [1][4]. - The company’s other drug, Endu® (recombinant human vascular endothelial growth factor inhibitor injection), has successfully completed its renewal in the National Reimbursement Drug List (NRDL) [1][4]. Group 2: Market Position and Significance - Enze Shu® is described as a next-generation recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), highlighting its innovative nature in cancer treatment [1][4]. - Endu® is noted as the first anti-angiogenic targeted drug in China and the only endothelial inhibitor approved for sale globally, establishing its importance in the treatment of advanced non-small cell lung cancer since its inclusion in the NRDL in 2017 [1][4].

Core Insights - The company reported a revenue of 3.585 billion yuan for the first half of 2025, representing a year-on-year growth of 15.1%, with a net profit attributable to shareholders of 604 million yuan, up 32.2% year-on-year [1] - The innovative drug business was a significant growth driver, generating 2.776 billion yuan in revenue, a 26.0% increase, accounting for 77.4% of total revenue [1] Revenue Breakdown - The neuroscience segment generated 1.249 billion yuan, accounting for 34.8% of total revenue, with a year-on-year growth of 37.3% [2] - The oncology segment reported revenue of 874 million yuan, making up 24.4% of total revenue, with a growth of 41.1% [2] - The autoimmune segment achieved revenue of 878 million yuan, representing 24.5% of total revenue, with a modest growth of 3.3% [2] Product Highlights - The strong growth in the neuroscience field is attributed to the continued expansion of the product Xianbixin® in the stroke injection market, which has captured approximately 29% market share [2] - The oncology segment features several key products, including Endu® and Envida®, which are recommended in multiple clinical practice guidelines [3] - The autoimmune segment's leading product, Aidesin®, has benefited over 1 million patients since its launch in 2012 [3] R&D Investment - The company increased its R&D investment to 1.028 billion yuan, a 68.0% increase year-on-year, representing 28.7% of total revenue [4] - Over the past decade, cumulative R&D investment has exceeded 10 billion yuan, supporting ongoing innovation [4] - The company has ten approved innovative drugs and over 60 projects in its pipeline [4] Strategic Collaborations - The company has established strategic partnerships with various international firms, enhancing its R&D pipeline and international presence [6] - Notable collaborations include licensing agreements with AbbVie and NextCure for innovative drug candidates [6] Marketing and Financial Health - The company has a comprehensive marketing network with approximately 4,179 personnel across China, covering over 3,000 tertiary hospitals and 17,000 other medical institutions [7] - As of June 30, 2025, the company reported cash and cash equivalents of 2.671 billion yuan, with a net operating cash flow of 867 million yuan [7] Industry Environment - The Chinese pharmaceutical industry is experiencing favorable policy changes that support innovative drug development, including expedited review processes [8] - The company aims to expand its market share and improve drug accessibility through its strong R&D capabilities and commercial strategies [8]

Core Insights - The approval of Enzeshou® (suvorexant injection) by the National Medical Products Administration (NMPA) in China marks a significant advancement in the treatment of platinum-resistant ovarian cancer, providing a much-needed therapeutic option for patients who have undergone limited prior systemic treatment [1][2] - Enzeshou® is a next-generation recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), demonstrating superior efficacy compared to existing treatments like Bevacizumab in preclinical studies [2] Group 1: Drug Approval and Indications - Enzeshou® received approval on June 30, 2025, for use in adult patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are platinum-resistant and have received no more than one prior systemic therapy [1] - The drug addresses a significant unmet clinical need in China, as there are currently no approved anti-angiogenic therapies for platinum-resistant ovarian cancer, particularly for patients previously treated with anti-angiogenic therapies [1] Group 2: Clinical Efficacy - The Phase III clinical trial (SCORES study) demonstrated significant improvements in progression-free survival (PFS), with median PFS extending from 2.73 months to 5.49 months, and a hazard ratio (HR) of 0.46 (0.35, 0.60), with a p-value of less than 0.0001 [2] - The trial also indicated a 23% reduction in the risk of death for the treatment group compared to the control group, with an overall survival (OS) hazard ratio of 0.77 and a p-value of 0.0304, marking Enzeshou® as the first vascular-targeted drug to show significant OS benefits in the platinum-resistant ovarian cancer population [2]